Dimopoulos, M., Siegel, D., White, D. J., Boccia, R., Iskander, K. S., Yang, Z., Kimball, A. S., Mezzi, K., Ludwig, H., & Niesvizky, R. (2019). Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: A subgroup analysis of ENDEAVOR. Blood, 133(2), 147-155. https://doi.org/10.1182/blood-2018-06-860015
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: A subgroup analysis of ENDEAVOR. / Dimopoulos, Meletios; Siegel, David
; White, Darrell J. et al.
In:
Blood, Vol. 133, No. 2, 10.01.2019, p. 147-155.
Research output: Contribution to journal › Article › peer-review
Dimopoulos, M, Siegel, D, White, DJ, Boccia, R, Iskander, KS, Yang, Z, Kimball, AS, Mezzi, K, Ludwig, H & Niesvizky, R 2019, 'Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: A subgroup analysis of ENDEAVOR', Blood, vol. 133, no. 2, pp. 147-155. https://doi.org/10.1182/blood-2018-06-860015
Dimopoulos M, Siegel D, White DJ, Boccia R, Iskander KS, Yang Z et al. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: A subgroup analysis of ENDEAVOR. Blood. 2019 Jan 10;133(2):147-155. doi: 10.1182/blood-2018-06-860015
Dimopoulos, Meletios ; Siegel, David ; White, Darrell J. et al. / Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure : A subgroup analysis of ENDEAVOR. In: Blood. 2019 ; Vol. 133, No. 2. pp. 147-155.
@article{4bfe63d181ba4d529a29312b16db981b,
title = "Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: A subgroup analysis of ENDEAVOR",
author = "Meletios Dimopoulos and David Siegel and White, {Darrell J.} and Ralph Boccia and Iskander, {Karim S.} and Zhao Yang and Kimball, {Amy S.} and Khalid Mezzi and Heinz Ludwig and Ruben Niesvizky",
note = "Publisher Copyright: {\textcopyright} 2019 by The American Society of Hematology.",
year = "2019",
month = jan,
day = "10",
doi = "10.1182/blood-2018-06-860015",
language = "English",
volume = "133",
pages = "147--155",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",
}
TY - JOUR
T1 - Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure
T2 - A subgroup analysis of ENDEAVOR
AU - Dimopoulos, Meletios
AU - Siegel, David
AU - White, Darrell J.
AU - Boccia, Ralph
AU - Iskander, Karim S.
AU - Yang, Zhao
AU - Kimball, Amy S.
AU - Mezzi, Khalid
AU - Ludwig, Heinz
AU - Niesvizky, Ruben
N1 - Publisher Copyright:
© 2019 by The American Society of Hematology.
PY - 2019/1/10
Y1 - 2019/1/10
UR - http://www.scopus.com/inward/record.url?scp=85059805866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059805866&partnerID=8YFLogxK
U2 - 10.1182/blood-2018-06-860015
DO - 10.1182/blood-2018-06-860015
M3 - Article
C2 - 30478094
AN - SCOPUS:85059805866
SN - 0006-4971
VL - 133
SP - 147
EP - 155
JO - Blood
JF - Blood
IS - 2
ER -